Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (...
Q1 2026
May 13, 2026
FY 2025
Mar 25, 2026
Q4 2025
Q3 2025
Nov 13, 2025
Q2 2025
Aug 14, 2025